Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2013-2023
How and why the AMD and DR market can expand - you discover its potential
Where are treatments for macular degeneration (AMD) and diabetic retinopathy (DR) heading? Visiongain's updated report gives you revenue predictions to 2023 for those eye disorders. There you find data, trends, opportunities and commercial prospects.
That new study lets you assess forecasted sales at overall world market, submarket, product and national level. You discover the potential of that ophthalmic drug market, seeing how and why it can grow. Product demand is increasing.
Forecasts and other analyses to help your work
In our investigation you find revenue forecasting to 2023, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business outlooks and research and development (R&D). You receive 39 tables, 35 charts and three research interviews.
We show where revenue growth can occur for treating those retinal disorders. You investigate the most lucrative areas of that industry and market segment. Its technologies hold great promise.
You can stay ahead in knowledge, benefiting your research and analyses. The following sections highlight what you discover in our report.
Find prospects for therapeutic submarkets and leading products
In addition to analyses of the overall world market, you see revenue forecasting of three world-level submarkets to 2023:
In our report you assess competition, as well as commercial drivers and restraints. The work also breaks the overall world market into leading national segments.
What are the prospects in leading regions and countries?
There are many commercial opportunities for those medicines in developed and developing countries. Strong prospects exist for pharmaceutical companies, our report explains.
You discover individual revenue forecasts to 2023 for leading national markets:
Product launches from 2012 onwards will benefit regional and national markets. There is high, rising demand for retinal treatments, including new agents.
Research and development activities - see trends and possibilities
What's happening in the R&D pipeline? You see developmental trends there, including:
What will affect that ophthalmic products industry and market?
Leading companies and market value in 2015
What will happen next? The biopharma industry will improve treatments for AMD and DR, increasing revenues there from 2012 to 2023. The R&D pipeline is strong.
Overall world revenue for that market area will reach $6.25bn in 2015, our report forecasts. Ageing populations, diabetes and improving healthcare will increase sales of retinal drugs.
In our study you find discussions of Roche, Novartis, Pfizer, Regeneron, Allergan and many other developers and manufacturers, including specialists. Also, you see our interviews.
From 2012, pharma corporations and specialty firms will develop and prosper from ocular medicines. You discover how.
Eight ways Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2013-2023 helps you
In particular, then, our report gives you the following knowledge on the topic:
With our report you are less likely to fall behind in knowledge. Discover how our work could benefit your research and analyses in ophthalmics, saving you time too.
Ordering now lets you investigate prospects for drugs treating AMD and DR
Visiongain's study is for everyone needing analysis of the industry and market for treating retinal diseases. You find data, trends and predictions. Please order our report now.
Where are treatments for macular degeneration (AMD) and diabetic retinopathy (DR) heading? Visiongain's updated report gives you revenue predictions to 2023 for those eye disorders. There you find data, trends, opportunities and commercial prospects.
That new study lets you assess forecasted sales at overall world market, submarket, product and national level. You discover the potential of that ophthalmic drug market, seeing how and why it can grow. Product demand is increasing.
Forecasts and other analyses to help your work
In our investigation you find revenue forecasting to 2023, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business outlooks and research and development (R&D). You receive 39 tables, 35 charts and three research interviews.
We show where revenue growth can occur for treating those retinal disorders. You investigate the most lucrative areas of that industry and market segment. Its technologies hold great promise.
You can stay ahead in knowledge, benefiting your research and analyses. The following sections highlight what you discover in our report.
Find prospects for therapeutic submarkets and leading products
In addition to analyses of the overall world market, you see revenue forecasting of three world-level submarkets to 2023:
- Wet AMD
- Dry AMD
- DR.
In our report you assess competition, as well as commercial drivers and restraints. The work also breaks the overall world market into leading national segments.
What are the prospects in leading regions and countries?
There are many commercial opportunities for those medicines in developed and developing countries. Strong prospects exist for pharmaceutical companies, our report explains.
You discover individual revenue forecasts to 2023 for leading national markets:
- US
- Japan
- Germany, France, UK, Italy and Spain (EU5)
- Brazil, Russia, India and China (BRIC nations, grouped analysis).
Product launches from 2012 onwards will benefit regional and national markets. There is high, rising demand for retinal treatments, including new agents.
Research and development activities - see trends and possibilities
What's happening in the R&D pipeline? You see developmental trends there, including:
- Anti-VEGF treatments
- Recombinant human VEGF receptor-Fc fusion proteins
- Treatments targeting other growth factors
- Gene therapies, corticosteroids and integrin antagonists
- Kinase and mTOR inhibitors
- Small interfering RNAs (siRNAs)
- Complement inhibitors
- Neuroprotectants and regenerative medicine.
What will affect that ophthalmic products industry and market?
- Our work discusses many issues affecting the sector from 2012 onwards:
- Biological drugs (biologics), especially monoclonal antibodies (mAbs)
- Novel technologies - stem cells, small proteins and single-chain antibody fragments
- Improved drug delivery, including eye drop formulations
- Combination therapies and new ways to protect the retina and stop vision loss
- Neuroprotection and reversal of damage with regenerative medical technology
- Control of diabetic macular oedema (DME)
- Off-label treatments and reimbursement matters.
Leading companies and market value in 2015
What will happen next? The biopharma industry will improve treatments for AMD and DR, increasing revenues there from 2012 to 2023. The R&D pipeline is strong.
Overall world revenue for that market area will reach $6.25bn in 2015, our report forecasts. Ageing populations, diabetes and improving healthcare will increase sales of retinal drugs.
In our study you find discussions of Roche, Novartis, Pfizer, Regeneron, Allergan and many other developers and manufacturers, including specialists. Also, you see our interviews.
From 2012, pharma corporations and specialty firms will develop and prosper from ocular medicines. You discover how.
Eight ways Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2013-2023 helps you
In particular, then, our report gives you the following knowledge on the topic:
- Forecasted revenues to 2023 for the overall world market and 3 therapeutic submarkets - find the industry's sales prospects
- Predicted revenues of 3 leading products to 2023 - analyse crucial developments
- Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy (EU5) and the BRIC group - see leading national prospects
- Assessment of companies - find activities, products, strategies and outlooks
- Review of R&D pipelines - investigate developmental trends and progress
- Opinions on the sector - discover our interviews with authorities in the field
- Investigation of competition and opportunities influencing sales
- Discussions of what stimulates and restrains the industry and market.
With our report you are less likely to fall behind in knowledge. Discover how our work could benefit your research and analyses in ophthalmics, saving you time too.
Ordering now lets you investigate prospects for drugs treating AMD and DR
Visiongain's study is for everyone needing analysis of the industry and market for treating retinal diseases. You find data, trends and predictions. Please order our report now.
1. EXECUTIVE SUMMARY
1.1 Macular Degeneration (AMD) and Diabetic Retinopathy (DR): Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. AMD AND DR: OVERVIEW
2.1 The Human Eye
2.1.1 The Retina and the Vision Process
2.2 Age-Related Macular Degeneration (AMD)
2.2.1 Early Stages of AMD
2.2.2 Advanced Dry AMD (Geographic Atrophy)
2.2.3 Wet AMD
2.2.4 Causes and Risk Factors for AMD
2.3 Diabetic Retinopathy (DR)
2.3.1 Causes and Types of DR
2.3.2 Non-Proliferative Diabetic Retinopathy (NPDR)
2.3.3 Diabetic Macular Oedema (DME)
2.3.4 Proliferative Diabetic Retinopathy (PDR)
2.3.5 Risk Factors for DR
2.4 Diagnosis
2.5 Epidemiology
3. THE GLOBAL AMD AND DR MARKET 2013-2023
3.1 Global AMD and DR Market, 2013-2023
3.2 Segment Analysis, 2013-2023
3.3 Leading Products, 2012
3.4 Leading Companies, 2012
3.4.1 Novartis and Roche, 2012
3.4.2 Regeneron and Bayer, 2012
3.4.3 Pfizer and Other Big Pharma Players, 2012
3.4.4 Ophthalmic Specialists, 2012
3.4.5 Biotech Companies, 2012
3.4.6 Valeant Pharma
3.5 Leading Regional Markets, 2012-2023
3.5.1 The US Market, 2013-2023
3.5.2 The Japanese Market, 2013-2023
3.5.3 The EU5 Market, 2013-2023
3.5.4 The BRIC Nations Market, 2013-2023
4. CURRENTLY APPROVED PRODUCTS IN THE AMD AND DR WORLD DRUG MARKET, 2013-2023
4.1 Market Forecast for Existing Products, 2013-2023
4.2 Overview: Head-to-Head-to-Head - Lucentis, Eylea and Avastin for the Anti-VEGF Market, 2012
4.3 Lucentis (Roche/Novartis), 2013-2023
4.3.1 Lucentis Indications
4.3.2 Lucentis Market Performance 2011-2012
4.3.3 Drivers and Restraints for Lucentis, 2012
4.3.4 Market Forecast for Lucentis, 2013-2023
4.4 Eylea (Regeneron/Bayer), 2013-2023
4.4.1 Eylea Indications
4.4.2 Eylea Market Performance 2011-2012
4.4.3 Drivers and Restraints for Eylea, 2012
4.4.4 Market Forecast for Eylea, 2013-2023
4.5 Avastin (Roche), 2013-2023
4.5.1 The CATT Study Year Two: The Final Verdict on Avastin vs. Lucentis?
4.5.2 Drivers and Restraints for Avastin, 2012
4.5.3 Market Forecast for Avastin, 2013-2023
4.6 Other Approved Products, 2013-2023
5. WET AMD MARKET, 2013-2023
5.1 Wet AMD Market Forecast, 2013-2023
5.2 Wet AMD Overview, 2012
5.3 Expanding the Anti-VEGF Treatment Options
5.3.1 Recombinant Human VEGF Receptor-Fc Fusion Protein (Chengdu Kanghong Biotech)
5.3.2 AGN-150998 DARPin (Allergan): Impressively Extended Half-Life
5.3.3 Squalamine (OHR Pharmaceutical): A Topical Option?
5.3.4 ESBA 1008 (Alcon): Innovative Fragment Technology
5.3.5 PDS 1.0 (ForSight VISION4): New Delivery Options
5.3.6 Pan-90806 (PanOptica): Preclinical Topical Approach
5.4 Treatments Targeting Other Growth Factors
5.4.1 Fovista (Ophthotech): The Next Game-Changer?
5.4.2 iSONEP (Lpath): Targeting S1P
5.5 Gene Therapies: A New Frontier in Wet AMD Treatment?
5.5.1 AVA-101(Avalanche Biotechnologies): Ocular BioFactory Technology
5.5.2 AAV2-sFLT01 (Genzyme): Will Complete Phase I in 2012
5.5.3 RetinoStat (Oxford BioMedica): Delivering Two Anti-Angiogenic Genes to the Retina
5.6 Corticosteroids: Updating an Established Approach
5.6.1 Ozurdex (Allergan): Sustained-Release Implant
5.6.2 IBI-20089 (Icon Bioscience): Clinical Possibilities in 20 Eye Diseases
5.7 Integrin Antagonists: Hitting Endothelial Cell Survival Pathways
5.7.1 Volociximab (Ophthotech): A New Option in Cancer and CNV
5.7.2 JSM6427 (Shire): From the Peptide-to-Drug Platform
5.8 Kinase Inhibitors: Targeting VEGF Upstream
5.8.1 Pazopanib (GlaxoSmithKline): Leading Kinase Inhibitor
5.8.2 AL-39324 (Alcon): Completed WALTZ Trial in 2011
5.8.3 Vatalanib (Novartis): An Angiogenesis Blocker
5.8.4 TG100801 (Sanofi): Topical Kinase Inhibitor
5.9 mTOR Inhibitors: Life After Rapamycin Termination?
5.10 Small Interfering RNAs (siRNAs): Great Promise, Little Clinical Achievement to Date
5.11 Complement Inhibitors: Blocking the Complement Cascade
5.11.1 AL-78898A (Alcon): First Ophthalmic Complement Inhibitor to be Trialled
5.11.2 ARC1905 (Ophthotech): Targeting Factor C5
5.12 Other Potential Wet AMD Treatments: A Variety of Approaches
5.12.1 Ocriplasmin (ThromboGenics): Approved in July 2012
5.12.2 LFG316 (Novartis): Phase II Completion in 2013
5.12.3 Allogeneic Stem Cells (Mesoblast): Singapore Stem Cell Trial
5.12.4 Zybrestat (Oxigene): Pro-drug with New Mechanism of Action
5.12.5 ATG-3 (CoMentis): Nicotine Cholinergic Receptor Antagonist
5.12.6 ORA102 (Ora Bio): Repurposing Old Drugs for AMD and Cancer
5.12.7 GS-101 (Gene Signal): Antisense Approach Based on Gene Discovery Innovations
6. DRY AMD MARKET, 2013-2023
6.1 Dry AMD Market Forecast, 2013-2023
6.2 Dry AMD Overview, 2012
6.3 Treatment for Vascular Insufficiency: A Universal Approach for Dry AMD?
6.3.1 MC-1101 (MacuCLEAR): In Phase III on Shortened FDA Approval Pathway
6.4 Complement Inhibitors: A Major R&D Approach in Dry AMD
6.4.1 AL-78898A (Alcon): Dry AMD Trial Underway in 2012
6.4.2 Soliris (Alexion): Another Dry AMD Candidate
6.4.3 FCFD4514S (Genentech): Anti-Factor D Fab Fragment
6.4.4 ARC1905 (Ophthotech): Anti-C5 Aptamer to Complete Safety Trial in 2012
6.5 Corticosteroids: Blocking Inflammatory Processes Key to Dry AMD Pathogenesis?
6.5.1 Medidur Fluocinolone Acetonide (Alimera Sciences): Phase II Trial to Conclude in 2014
6.5.2 AGN208397 (Allergan): 200 Times More Potent than Traditional Steroids
6.6 Oxidative Stress Treatments: The Only Verified Approach
6.7 Visual Cycle Modulators: Reducing Metabolic Load
6.7.1 Fenretinide (ReVision Therapeutics): Blocking Vitamin A Toxins
6.7.2 ACU-4429 (Acucela): Possible Better Side-Effect Profile than Other Visual Cycle Options
6.8 Neuroprotectants: A Key Field in R&D
6.8.1 Tandospirone (Alcon): Phase III Trial Completed 2012
6.8.2 NT501 (Neurotech): Using CNTF to Protect Retina
6.8.3 Brimonidine Tartrate (Allergan): Repurposed Glaucoma Drug
6.8.4 RN6G (Pfizer): Binding Amyloid Beta
6.8.5 VAR10200 (Varinel): Preclinical Neuroprotectant
6.9 Regenerative Medicine Treatments: Can Dry AMD be Reversed?
6.9.1 MA09-hRPE Cellular Therapy (Advanced Cell Technology): World-Leading Embryonic Stem Cell Programme
6.9.2 HuCNS-SC (StemCells): Neural Stem Cell Approach
6.9.3 Stemedyne-RPE (Stemedica Cell Technologies): Unique Ischemic-Tolerant Cell Lines
6.9.4 RetroSense Therapeutics: Piloting Optogenetics for Dry AMD
6.10 Other Products in the Dry AMD Pipeline
7. DR MARKET, 2013-2023
7.1 DR Market Forecast, 2013-2023
7.2 DR Overview, 2012
7.3 Anti-VEGF Treatments: Given Regulatory Approval in 2012
7.4 Corticosteroids: Longer-Acting than VEGF Blockers in DME
7.4.1 Iluvien (Alimera/pSivida): Gaining Approvals in Europe in 2012
7.4.2 Ozurdex (Allergan): Still Being Tested in DME
7.4.3 Betamethasone Microsphere (Santen): Another Novel Delivery System
7.4.4 SK-0503 (Sanwa Kagaku Kenkyusho): Possible DME and RVO Treatment
7.4.5 Cortiject (Novagali Pharma): Eyeject-Delivered Pro-drug
7.5 Integrin Antagonists: Possible DME Approach
7.5.1 SAR1118 (SARcode Bioscience): Blocking T-Cell Mediated Inflammation
7.5.2 ALG-1001 (Allegro Ophthalmics): Peptide Targeting Multiple Integrins
7.6 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Established Off-Label Treatments
7.7 A Range of Other DME Candidates are in Development
7.7.1 Vitreosolve (Innovations in Sight): Hoping to Remount Phase III Test
7.7.2 Choline Fenofibrate (Abbott): Repurposed Cholesterol Drug
7.7.3 iCo-007 Intravitreal Injection (iCo Therapeutics): Second-Generation Antisense Approach
7.7.4 Darapladib (GlaxoSmithKline): DME Applications for Atherosclerosis Candidate?
7.7.5 Bromfenac Ophthalmic Solution (ISTA Pharmaceuticals): Versatile Ophthalmic Product
8. INDUSTRY ANALYSIS
8.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
8.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
8.3 Opportunities: New Markets and R&D Synergies
8.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
8.5 Social: Low Diagnosis, Low Compliance
8.6 Technological: Innovation in the Eye
8.7 Economic: Off-Label Treatment and Reimbursement Issues
8.8 Political: The Demography and Diabetes Time-Bombs
9. RESEARCH INTERVIEWS FROM OUR SURVEY
9.1 Interview with Dr Michael Stewart, Mayo Clinic
9.1.1 The Impact of Eylea, 2011-2012
9.1.2 The Comparative Dosing Schedules of Eylea and Lucentis
9.1.3 Patient Transitioning to Eylea: Salvage Switching
9.1.4 Avastin After the CATT Study
9.1.5 Prospects for Eylea in Other Indications and Combinations
9.1.6 Future Possibilities in Wet AMD Treatment
9.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
9.2.1 MC-1101: Identifying and Treating Chiou Syndrome
9.2.2 Preventing Dry AMD Progression
9.2.3 Treating the Root Cause of Dry AMD
9.2.4 Phase III: Endpoints and Prospects for MC-1101
9.3 Interview with Sean Ainsworth, RetroSense Therapeutics
9.3.1 The Optogenetic Approach to Vision Restoration
9.3.2 Choosing Disease Targets and Delivery Vectors
9.3.3 The Regulatory Picture
9.3.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas
9.3.5 The Next Ten Years for Gene Therapy
10. CONCLUSIONS
10.1 Lucentis and Eylea Will Drive Impressive Growth in the AMD and DR Market to 2023
10.2 The R&D Pipeline is Strong, with Many Novel Candidates
10.3 Dry AMD and DR Treatment Will Become Increasingly Important to the Market
10.4 Bayer Set to Become an Important Market Presence, with China a Key Market
10.5 Global Demography and Diabetes Prevalence Will Drive Market Growth
1.1 Macular Degeneration (AMD) and Diabetic Retinopathy (DR): Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. AMD AND DR: OVERVIEW
2.1 The Human Eye
2.1.1 The Retina and the Vision Process
2.2 Age-Related Macular Degeneration (AMD)
2.2.1 Early Stages of AMD
2.2.2 Advanced Dry AMD (Geographic Atrophy)
2.2.3 Wet AMD
2.2.4 Causes and Risk Factors for AMD
2.3 Diabetic Retinopathy (DR)
2.3.1 Causes and Types of DR
2.3.2 Non-Proliferative Diabetic Retinopathy (NPDR)
2.3.3 Diabetic Macular Oedema (DME)
2.3.4 Proliferative Diabetic Retinopathy (PDR)
2.3.5 Risk Factors for DR
2.4 Diagnosis
2.5 Epidemiology
3. THE GLOBAL AMD AND DR MARKET 2013-2023
3.1 Global AMD and DR Market, 2013-2023
3.2 Segment Analysis, 2013-2023
3.3 Leading Products, 2012
3.4 Leading Companies, 2012
3.4.1 Novartis and Roche, 2012
3.4.2 Regeneron and Bayer, 2012
3.4.3 Pfizer and Other Big Pharma Players, 2012
3.4.4 Ophthalmic Specialists, 2012
3.4.5 Biotech Companies, 2012
3.4.6 Valeant Pharma
3.5 Leading Regional Markets, 2012-2023
3.5.1 The US Market, 2013-2023
3.5.2 The Japanese Market, 2013-2023
3.5.3 The EU5 Market, 2013-2023
3.5.4 The BRIC Nations Market, 2013-2023
4. CURRENTLY APPROVED PRODUCTS IN THE AMD AND DR WORLD DRUG MARKET, 2013-2023
4.1 Market Forecast for Existing Products, 2013-2023
4.2 Overview: Head-to-Head-to-Head - Lucentis, Eylea and Avastin for the Anti-VEGF Market, 2012
4.3 Lucentis (Roche/Novartis), 2013-2023
4.3.1 Lucentis Indications
4.3.2 Lucentis Market Performance 2011-2012
4.3.3 Drivers and Restraints for Lucentis, 2012
4.3.4 Market Forecast for Lucentis, 2013-2023
4.4 Eylea (Regeneron/Bayer), 2013-2023
4.4.1 Eylea Indications
4.4.2 Eylea Market Performance 2011-2012
4.4.3 Drivers and Restraints for Eylea, 2012
4.4.4 Market Forecast for Eylea, 2013-2023
4.5 Avastin (Roche), 2013-2023
4.5.1 The CATT Study Year Two: The Final Verdict on Avastin vs. Lucentis?
4.5.2 Drivers and Restraints for Avastin, 2012
4.5.3 Market Forecast for Avastin, 2013-2023
4.6 Other Approved Products, 2013-2023
5. WET AMD MARKET, 2013-2023
5.1 Wet AMD Market Forecast, 2013-2023
5.2 Wet AMD Overview, 2012
5.3 Expanding the Anti-VEGF Treatment Options
5.3.1 Recombinant Human VEGF Receptor-Fc Fusion Protein (Chengdu Kanghong Biotech)
5.3.2 AGN-150998 DARPin (Allergan): Impressively Extended Half-Life
5.3.3 Squalamine (OHR Pharmaceutical): A Topical Option?
5.3.4 ESBA 1008 (Alcon): Innovative Fragment Technology
5.3.5 PDS 1.0 (ForSight VISION4): New Delivery Options
5.3.6 Pan-90806 (PanOptica): Preclinical Topical Approach
5.4 Treatments Targeting Other Growth Factors
5.4.1 Fovista (Ophthotech): The Next Game-Changer?
5.4.2 iSONEP (Lpath): Targeting S1P
5.5 Gene Therapies: A New Frontier in Wet AMD Treatment?
5.5.1 AVA-101(Avalanche Biotechnologies): Ocular BioFactory Technology
5.5.2 AAV2-sFLT01 (Genzyme): Will Complete Phase I in 2012
5.5.3 RetinoStat (Oxford BioMedica): Delivering Two Anti-Angiogenic Genes to the Retina
5.6 Corticosteroids: Updating an Established Approach
5.6.1 Ozurdex (Allergan): Sustained-Release Implant
5.6.2 IBI-20089 (Icon Bioscience): Clinical Possibilities in 20 Eye Diseases
5.7 Integrin Antagonists: Hitting Endothelial Cell Survival Pathways
5.7.1 Volociximab (Ophthotech): A New Option in Cancer and CNV
5.7.2 JSM6427 (Shire): From the Peptide-to-Drug Platform
5.8 Kinase Inhibitors: Targeting VEGF Upstream
5.8.1 Pazopanib (GlaxoSmithKline): Leading Kinase Inhibitor
5.8.2 AL-39324 (Alcon): Completed WALTZ Trial in 2011
5.8.3 Vatalanib (Novartis): An Angiogenesis Blocker
5.8.4 TG100801 (Sanofi): Topical Kinase Inhibitor
5.9 mTOR Inhibitors: Life After Rapamycin Termination?
5.10 Small Interfering RNAs (siRNAs): Great Promise, Little Clinical Achievement to Date
5.11 Complement Inhibitors: Blocking the Complement Cascade
5.11.1 AL-78898A (Alcon): First Ophthalmic Complement Inhibitor to be Trialled
5.11.2 ARC1905 (Ophthotech): Targeting Factor C5
5.12 Other Potential Wet AMD Treatments: A Variety of Approaches
5.12.1 Ocriplasmin (ThromboGenics): Approved in July 2012
5.12.2 LFG316 (Novartis): Phase II Completion in 2013
5.12.3 Allogeneic Stem Cells (Mesoblast): Singapore Stem Cell Trial
5.12.4 Zybrestat (Oxigene): Pro-drug with New Mechanism of Action
5.12.5 ATG-3 (CoMentis): Nicotine Cholinergic Receptor Antagonist
5.12.6 ORA102 (Ora Bio): Repurposing Old Drugs for AMD and Cancer
5.12.7 GS-101 (Gene Signal): Antisense Approach Based on Gene Discovery Innovations
6. DRY AMD MARKET, 2013-2023
6.1 Dry AMD Market Forecast, 2013-2023
6.2 Dry AMD Overview, 2012
6.3 Treatment for Vascular Insufficiency: A Universal Approach for Dry AMD?
6.3.1 MC-1101 (MacuCLEAR): In Phase III on Shortened FDA Approval Pathway
6.4 Complement Inhibitors: A Major R&D Approach in Dry AMD
6.4.1 AL-78898A (Alcon): Dry AMD Trial Underway in 2012
6.4.2 Soliris (Alexion): Another Dry AMD Candidate
6.4.3 FCFD4514S (Genentech): Anti-Factor D Fab Fragment
6.4.4 ARC1905 (Ophthotech): Anti-C5 Aptamer to Complete Safety Trial in 2012
6.5 Corticosteroids: Blocking Inflammatory Processes Key to Dry AMD Pathogenesis?
6.5.1 Medidur Fluocinolone Acetonide (Alimera Sciences): Phase II Trial to Conclude in 2014
6.5.2 AGN208397 (Allergan): 200 Times More Potent than Traditional Steroids
6.6 Oxidative Stress Treatments: The Only Verified Approach
6.7 Visual Cycle Modulators: Reducing Metabolic Load
6.7.1 Fenretinide (ReVision Therapeutics): Blocking Vitamin A Toxins
6.7.2 ACU-4429 (Acucela): Possible Better Side-Effect Profile than Other Visual Cycle Options
6.8 Neuroprotectants: A Key Field in R&D
6.8.1 Tandospirone (Alcon): Phase III Trial Completed 2012
6.8.2 NT501 (Neurotech): Using CNTF to Protect Retina
6.8.3 Brimonidine Tartrate (Allergan): Repurposed Glaucoma Drug
6.8.4 RN6G (Pfizer): Binding Amyloid Beta
6.8.5 VAR10200 (Varinel): Preclinical Neuroprotectant
6.9 Regenerative Medicine Treatments: Can Dry AMD be Reversed?
6.9.1 MA09-hRPE Cellular Therapy (Advanced Cell Technology): World-Leading Embryonic Stem Cell Programme
6.9.2 HuCNS-SC (StemCells): Neural Stem Cell Approach
6.9.3 Stemedyne-RPE (Stemedica Cell Technologies): Unique Ischemic-Tolerant Cell Lines
6.9.4 RetroSense Therapeutics: Piloting Optogenetics for Dry AMD
6.10 Other Products in the Dry AMD Pipeline
7. DR MARKET, 2013-2023
7.1 DR Market Forecast, 2013-2023
7.2 DR Overview, 2012
7.3 Anti-VEGF Treatments: Given Regulatory Approval in 2012
7.4 Corticosteroids: Longer-Acting than VEGF Blockers in DME
7.4.1 Iluvien (Alimera/pSivida): Gaining Approvals in Europe in 2012
7.4.2 Ozurdex (Allergan): Still Being Tested in DME
7.4.3 Betamethasone Microsphere (Santen): Another Novel Delivery System
7.4.4 SK-0503 (Sanwa Kagaku Kenkyusho): Possible DME and RVO Treatment
7.4.5 Cortiject (Novagali Pharma): Eyeject-Delivered Pro-drug
7.5 Integrin Antagonists: Possible DME Approach
7.5.1 SAR1118 (SARcode Bioscience): Blocking T-Cell Mediated Inflammation
7.5.2 ALG-1001 (Allegro Ophthalmics): Peptide Targeting Multiple Integrins
7.6 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Established Off-Label Treatments
7.7 A Range of Other DME Candidates are in Development
7.7.1 Vitreosolve (Innovations in Sight): Hoping to Remount Phase III Test
7.7.2 Choline Fenofibrate (Abbott): Repurposed Cholesterol Drug
7.7.3 iCo-007 Intravitreal Injection (iCo Therapeutics): Second-Generation Antisense Approach
7.7.4 Darapladib (GlaxoSmithKline): DME Applications for Atherosclerosis Candidate?
7.7.5 Bromfenac Ophthalmic Solution (ISTA Pharmaceuticals): Versatile Ophthalmic Product
8. INDUSTRY ANALYSIS
8.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
8.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
8.3 Opportunities: New Markets and R&D Synergies
8.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
8.5 Social: Low Diagnosis, Low Compliance
8.6 Technological: Innovation in the Eye
8.7 Economic: Off-Label Treatment and Reimbursement Issues
8.8 Political: The Demography and Diabetes Time-Bombs
9. RESEARCH INTERVIEWS FROM OUR SURVEY
9.1 Interview with Dr Michael Stewart, Mayo Clinic
9.1.1 The Impact of Eylea, 2011-2012
9.1.2 The Comparative Dosing Schedules of Eylea and Lucentis
9.1.3 Patient Transitioning to Eylea: Salvage Switching
9.1.4 Avastin After the CATT Study
9.1.5 Prospects for Eylea in Other Indications and Combinations
9.1.6 Future Possibilities in Wet AMD Treatment
9.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
9.2.1 MC-1101: Identifying and Treating Chiou Syndrome
9.2.2 Preventing Dry AMD Progression
9.2.3 Treating the Root Cause of Dry AMD
9.2.4 Phase III: Endpoints and Prospects for MC-1101
9.3 Interview with Sean Ainsworth, RetroSense Therapeutics
9.3.1 The Optogenetic Approach to Vision Restoration
9.3.2 Choosing Disease Targets and Delivery Vectors
9.3.3 The Regulatory Picture
9.3.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas
9.3.5 The Next Ten Years for Gene Therapy
10. CONCLUSIONS
10.1 Lucentis and Eylea Will Drive Impressive Growth in the AMD and DR Market to 2023
10.2 The R&D Pipeline is Strong, with Many Novel Candidates
10.3 Dry AMD and DR Treatment Will Become Increasingly Important to the Market
10.4 Bayer Set to Become an Important Market Presence, with China a Key Market
10.5 Global Demography and Diabetes Prevalence Will Drive Market Growth
LIST OF TABLES
Table 2.1 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2012
Table 2.2 AMD and DR Diagnosis Methods, 2011
Table 2.3 Estimated AMD and DR Prevalence (m), 2010 and 2030
Table 3.1 AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), 2011-2016
Table 3.2 AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), 2017-2023
Table 3.3 AMD and DR Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.4 AMD and DR Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.5 Novartis AMD and DR Product Pipeline, 2012
Table 3.6 Pfizer AMD and DR Product Pipeline, 2012
Table 3.7 Other Big Pharma Companies: AMD and DR Product Pipeline, 2012
Table 3.8 Leading National Markets in the AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.9 Leading National Markets in the AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.10 US Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.11 US Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.12 Japanese Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.13 Japanese Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.14 EU5 Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.15 EU5 Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.16 EU5 Breakdown by Country: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.17 EU5 Breakdown by Country: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.18 BRIC Nations Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.19 BRIC Nations Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.1 Leading Products in the AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.2 Leading Products in the AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.3 Lucentis, Eylea and Avastin: Comparison of Key Characteristics
Table 4.4 Lucentis Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.5 Lucentis Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.6 Eylea Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.7 Eylea Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.8 Avastin Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.9 Avastin Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.10 Other Products Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.11 Other Products Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 5.1 Wet AMD Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 5.2 Wet AMD Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 6.1 Dry AMD Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 6.2 Dry AMD Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 7.1 DR Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 7.2 DR Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 2.1 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2012
Table 2.2 AMD and DR Diagnosis Methods, 2011
Table 2.3 Estimated AMD and DR Prevalence (m), 2010 and 2030
Table 3.1 AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), 2011-2016
Table 3.2 AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), 2017-2023
Table 3.3 AMD and DR Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.4 AMD and DR Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.5 Novartis AMD and DR Product Pipeline, 2012
Table 3.6 Pfizer AMD and DR Product Pipeline, 2012
Table 3.7 Other Big Pharma Companies: AMD and DR Product Pipeline, 2012
Table 3.8 Leading National Markets in the AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.9 Leading National Markets in the AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.10 US Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.11 US Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.12 Japanese Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.13 Japanese Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.14 EU5 Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.15 EU5 Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.16 EU5 Breakdown by Country: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.17 EU5 Breakdown by Country: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 3.18 BRIC Nations Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 3.19 BRIC Nations Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.1 Leading Products in the AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.2 Leading Products in the AMD and DR Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.3 Lucentis, Eylea and Avastin: Comparison of Key Characteristics
Table 4.4 Lucentis Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.5 Lucentis Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.6 Eylea Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.7 Eylea Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.8 Avastin Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.9 Avastin Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 4.10 Other Products Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 4.11 Other Products Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 5.1 Wet AMD Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 5.2 Wet AMD Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 6.1 Dry AMD Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 6.2 Dry AMD Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
Table 7.1 DR Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2011-2016
Table 7.2 DR Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2017-2023
LIST OF FIGURES
Figure 2.1 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
Figure 2.2 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
Figure 2.3 Stages and Progression of AMD
Figure 2.4 Types of CNV in Wet AMD, Approximate Proportion of Cases (%), 2012
Figure 2.5 Estimated AMD and DR Prevalence (m), 2010 and 2030
Figure 2.6 Estimated AMD and DR Disease Subtype Prevalence (m), 2010 and 2030
Figure 3.1 AMD and DR Market: Revenues ($m), 2011-2023
Figure 3.2 AMD and DR Market by Segment: Revenues ($m), Market Share (%), 2011
Figure 3.3 AMD and DR Market by Segment: Revenues ($m), 2011-2016
Figure 3.4 AMD and DR Market by Segment: Revenues ($m), 2017-2023
Figure 3.5 Leading Products in the AMD and DR Market: Revenues ($m), Market Share (%), 2011
Figure 3.6 Leading Products in the AMD and DR Market: Revenues ($m), Market Share (%), 2012
Figure 3.7 Leading Companies in the AMD and DR Market: Revenues ($m), Market Share (%), 2011
Figure 3.8 Leading Companies in the AMD and DR Market: Revenues ($m), Market Share (%), 2012
Figure 3.9 Leading National Markets in the AMD and DR Market: Revenues ($m), Market Share (%), 2011
Figure 3.10 Leading National Markets in the AMD and DR Market: Revenues ($m), 2011-2023
Figure 3.11 US Market Forecast: Revenues ($m), 2011-2023
Figure 3.12 Japanese Market Forecast: Revenues ($m), 2011-2023
Figure 3.13 EU5 Breakdown: Revenues ($m), Market Share (%), 2011
Figure 3.14 EU5 Market Forecast: Revenues ($m), 2011-2023
Figure 3.15 EU5 Breakdown: Revenues ($m), 2011-2023
Figure 3.16 BRIC Nations Breakdown: Revenues ($m), Market Share (%), 2011
Figure 3.17 BRIC Nations Market Forecast: Revenues ($m), 2011-2023
Figure 4.1 Leading Products in the AMD and DR Market: Revenues ($m), 2011-2023
Figure 4.2 Drivers and Restraints for Lucentis, 2012
Figure 4.3 Lucentis Market Forecast: Revenues ($m), 2011-2023
Figure 4.4 Overview of Eylea Launch and Market Penetration, 2011-2015
Figure 4.5 Drivers and Restraints for Eylea, 2012
Figure 4.6 Eylea Market Forecast: Revenues ($m), 2011-2023
Figure 4.7 Drivers and Restraints for Avastin, 2012
Figure 4.8 Avastin Market Forecast: Revenues ($m), 2011-2023
Figure 4.9 Other Products Market Forecast: Revenues ($m), 2011-2023
Figure 5.1 Wet AMD Market Forecast: Revenues ($m), 2011-2023
Figure 6.1 Dry AMD Market Forecast: Revenues ($m), 2011-2023
Figure 7.1 DR Market Forecast: Revenues ($m), 2011-2023
COMPANIES LISTED
Abbott Laboratories
Acucela
Adnexus
Advanced Cell Technology
Alcon
Alexion
Alimera Sciences
Alkeus Pharmaceuticals
Allegro Ophthalmics
Allergan
AMD Alliance International
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
Applied Genetic Technologies
Association for Research in Vision and Ophthalmology (ARVO)
AstraZeneca
Athenagen
Atlantis Pharma
ATON Pharma
Avalanche Biotechnologies
Bausch & Lomb
Bayer
Bayer Yakuhin (Bayer subsidiary)
Biogen Idec
Biovail Corporation
Bristol-Myers Squibb
Casey Eye Institute at Oregon Health and Science University
Chengdu Kanghong Biotech
Columbia University
CoMentis
Eli Lilly
Emory University
ESBATech
European Court of Justice
European Medicines Agency (EMEA/EMA)
Eyetech
Food and Drug Administration (US FDA)
Formatech
ForSight Labs
ForSight VISION4
Fovea
Genaera
Gene Signal
Genentech
GenVec
Genzyme
Geron
Gerot Lannach
GlaxoSmithKline
Human Genome Sciences
iCo Therapeutics
Icon Bioscience
Innovations in Sight
Institute of Ocular Pharmacology
ISTA Pharmaceuticals
Jerini
John Hopkins University
Kaplan Medical Center
Lions Eye Institute
Lpath
Ludwig-Maximilians - University of Munich
MacuCLEAR
MacuSight
Mayo Clinic
MedImmune
Merck & Co.
Mesoblast
Molecular Partners
Mystic Pharmaceuticals
National Eye Institute (US)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institutes of Health (NIH, US)
Natur Produk
Neuron Systems
Neurotech
Novagali Pharma
Novartis
Numoda Capital Innovations
Oakwood Laboratories
OcuSciences
OHR Pharmaceutical
Oklahoma Medical Research Foundation
Ophthotech Corporation
OPKO Health
Ora Bio
OraPharma
Österreichische Agentur für Gesundheit und Ernährungssicherheit, AGES
Othera Pharmaceuticals
Otsuka Pharmaceutical
Oxford BioMedica
Oxigene
Paloma Pharmaceuticals
Palomid Pharmaceuticals
PanOptica
PDL BioPharma
Pedinol Pharmacal
Pele Nova Biotecnologica
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pieris
Potentia Pharmaceuticals
Prevent Blindness America
Probiotica Laboratorios
pSivida
Purdue University
QLT
Quark
Regeneron
Retina Macula Institute
RetroSense Therapeutics
ReVision Therapeutics
Roche
Sanofi
Santen Pharmaceuticals
Sanwa Kagaku Kenkyusho
SARcode Bioscience
Shire
Singapore Eye Research Institute (SERI)
Singapore National Eye Centre
Sirion Therapeutics
Sirna Therapeutics
StemCells
Stemedica Cell Technologies
Symphony ViDA
Takeda
TargeGen
Teva Pharmaceutical Industries
ThromboGenics
UCB
University College London (UCL)
University of California, Los Angeles
University of Florida
University of Kentucky College of Medicine
University of Michigan
Valeant Pharmaceuticals International
Varinel
Vitreoretinal Technologies
World Health Organization (WHO)
Figure 2.1 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
Figure 2.2 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
Figure 2.3 Stages and Progression of AMD
Figure 2.4 Types of CNV in Wet AMD, Approximate Proportion of Cases (%), 2012
Figure 2.5 Estimated AMD and DR Prevalence (m), 2010 and 2030
Figure 2.6 Estimated AMD and DR Disease Subtype Prevalence (m), 2010 and 2030
Figure 3.1 AMD and DR Market: Revenues ($m), 2011-2023
Figure 3.2 AMD and DR Market by Segment: Revenues ($m), Market Share (%), 2011
Figure 3.3 AMD and DR Market by Segment: Revenues ($m), 2011-2016
Figure 3.4 AMD and DR Market by Segment: Revenues ($m), 2017-2023
Figure 3.5 Leading Products in the AMD and DR Market: Revenues ($m), Market Share (%), 2011
Figure 3.6 Leading Products in the AMD and DR Market: Revenues ($m), Market Share (%), 2012
Figure 3.7 Leading Companies in the AMD and DR Market: Revenues ($m), Market Share (%), 2011
Figure 3.8 Leading Companies in the AMD and DR Market: Revenues ($m), Market Share (%), 2012
Figure 3.9 Leading National Markets in the AMD and DR Market: Revenues ($m), Market Share (%), 2011
Figure 3.10 Leading National Markets in the AMD and DR Market: Revenues ($m), 2011-2023
Figure 3.11 US Market Forecast: Revenues ($m), 2011-2023
Figure 3.12 Japanese Market Forecast: Revenues ($m), 2011-2023
Figure 3.13 EU5 Breakdown: Revenues ($m), Market Share (%), 2011
Figure 3.14 EU5 Market Forecast: Revenues ($m), 2011-2023
Figure 3.15 EU5 Breakdown: Revenues ($m), 2011-2023
Figure 3.16 BRIC Nations Breakdown: Revenues ($m), Market Share (%), 2011
Figure 3.17 BRIC Nations Market Forecast: Revenues ($m), 2011-2023
Figure 4.1 Leading Products in the AMD and DR Market: Revenues ($m), 2011-2023
Figure 4.2 Drivers and Restraints for Lucentis, 2012
Figure 4.3 Lucentis Market Forecast: Revenues ($m), 2011-2023
Figure 4.4 Overview of Eylea Launch and Market Penetration, 2011-2015
Figure 4.5 Drivers and Restraints for Eylea, 2012
Figure 4.6 Eylea Market Forecast: Revenues ($m), 2011-2023
Figure 4.7 Drivers and Restraints for Avastin, 2012
Figure 4.8 Avastin Market Forecast: Revenues ($m), 2011-2023
Figure 4.9 Other Products Market Forecast: Revenues ($m), 2011-2023
Figure 5.1 Wet AMD Market Forecast: Revenues ($m), 2011-2023
Figure 6.1 Dry AMD Market Forecast: Revenues ($m), 2011-2023
Figure 7.1 DR Market Forecast: Revenues ($m), 2011-2023
COMPANIES LISTED
Abbott Laboratories
Acucela
Adnexus
Advanced Cell Technology
Alcon
Alexion
Alimera Sciences
Alkeus Pharmaceuticals
Allegro Ophthalmics
Allergan
AMD Alliance International
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
Applied Genetic Technologies
Association for Research in Vision and Ophthalmology (ARVO)
AstraZeneca
Athenagen
Atlantis Pharma
ATON Pharma
Avalanche Biotechnologies
Bausch & Lomb
Bayer
Bayer Yakuhin (Bayer subsidiary)
Biogen Idec
Biovail Corporation
Bristol-Myers Squibb
Casey Eye Institute at Oregon Health and Science University
Chengdu Kanghong Biotech
Columbia University
CoMentis
Eli Lilly
Emory University
ESBATech
European Court of Justice
European Medicines Agency (EMEA/EMA)
Eyetech
Food and Drug Administration (US FDA)
Formatech
ForSight Labs
ForSight VISION4
Fovea
Genaera
Gene Signal
Genentech
GenVec
Genzyme
Geron
Gerot Lannach
GlaxoSmithKline
Human Genome Sciences
iCo Therapeutics
Icon Bioscience
Innovations in Sight
Institute of Ocular Pharmacology
ISTA Pharmaceuticals
Jerini
John Hopkins University
Kaplan Medical Center
Lions Eye Institute
Lpath
Ludwig-Maximilians - University of Munich
MacuCLEAR
MacuSight
Mayo Clinic
MedImmune
Merck & Co.
Mesoblast
Molecular Partners
Mystic Pharmaceuticals
National Eye Institute (US)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institutes of Health (NIH, US)
Natur Produk
Neuron Systems
Neurotech
Novagali Pharma
Novartis
Numoda Capital Innovations
Oakwood Laboratories
OcuSciences
OHR Pharmaceutical
Oklahoma Medical Research Foundation
Ophthotech Corporation
OPKO Health
Ora Bio
OraPharma
Österreichische Agentur für Gesundheit und Ernährungssicherheit, AGES
Othera Pharmaceuticals
Otsuka Pharmaceutical
Oxford BioMedica
Oxigene
Paloma Pharmaceuticals
Palomid Pharmaceuticals
PanOptica
PDL BioPharma
Pedinol Pharmacal
Pele Nova Biotecnologica
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pieris
Potentia Pharmaceuticals
Prevent Blindness America
Probiotica Laboratorios
pSivida
Purdue University
QLT
Quark
Regeneron
Retina Macula Institute
RetroSense Therapeutics
ReVision Therapeutics
Roche
Sanofi
Santen Pharmaceuticals
Sanwa Kagaku Kenkyusho
SARcode Bioscience
Shire
Singapore Eye Research Institute (SERI)
Singapore National Eye Centre
Sirion Therapeutics
Sirna Therapeutics
StemCells
Stemedica Cell Technologies
Symphony ViDA
Takeda
TargeGen
Teva Pharmaceutical Industries
ThromboGenics
UCB
University College London (UCL)
University of California, Los Angeles
University of Florida
University of Kentucky College of Medicine
University of Michigan
Valeant Pharmaceuticals International
Varinel
Vitreoretinal Technologies
World Health Organization (WHO)
